Legend Biotech Corp (LEGN) stock
LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.11+0.12 (+0.75%)
Close on Nov 17, 2026Market cap $2.98BP/E –Yield –
Earnings
Legend Biotech's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 11, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
$387.50M
+51.9% on a year earlier
Adjusted EPS, Q2 FY2026
$0.16
$0.03 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Legend Biotech's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 11, 2026Expected | – | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 11, 2026before the open | $387.50M | +51.9% | $0.09 | $0.16 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 12, 2026before the open | $305.10M | +56.4% | -$0.15 | -$0.03 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 10, 2026before the open | $306.30M | +64.2% | -$0.08 | $0.01 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 12, 2025before the open | $272.33M | +70.0% | -$0.11 | -$0.05 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 11, 2025before the open | $255.06M | – | -$0.34 | $0.03 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 13, 2025before the open | $195.05M | +107.5% | -$0.27 | -$0.07 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 11, 2025before the open | $186.52M | – | $0.07 | -$0.15 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024before the open | $160.21M | – | -$0.34 | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 26, 2024before the open | – | – | – | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 13, 2024before the open | $93.99M | – | -$0.16 | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 11, 2024before the open | – | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 20, 2023before the open | – | – | – | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 15, 2023before the open | – | – | – | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 18, 2023before the open | – | – | – | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 30, 2023after the close | – | – | – | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 5, 2022before the open | – | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 18, 2022before the open | – | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Legend Biotech has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Legend Biotech puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Legend Biotech filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
See a number that looks wrong?